Page last updated: 2024-08-05 12:02:50
benzochromene
null
ChEBI ID: 38920
Members (5)
| Member | Definition | Role |
|---|---|---|
| delta(9)-tetrahydrocannabinolic acid | A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. A biosynthetic precursor to Delta(9)-tetrahydrocannabinol, the principal psychoactive constituent of the cannabis plant. | Delta(9)-tetrahydrocannabinolic acid |
| dronabinol | A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy. | Delta(9)-tetrahydrocannabinol |
| jwh-133 | A dibenzopyran that is Delta(9)-tetrahydrocannabinol which is lacking the hydroxy group and in which the pentyl group at position 3 has been replaced by a 1,1-dimethylbutyl group. A potent and highly selective CB2 receptor agonist. | JWH-133 |
| phenazopyridine | lapachenole | |
| rubimaillin | A benzochromene that is 2H-benzo[h]chromene which is substituted by two methyl groups at position 2, a methoxycarbonyl group at position 5, and a hydroxy group at position 6. Found in the Chinese medical plant Rubia cordifola, It has an anti-cancer effect by inhibition of TNF-alpha-induced NF-kappaB activation. It is also a dual inhibitor of acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), but is more selective for the ACAT2 isozyme. | rubimaillin |
Research
Studies (8,047)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2,252 (27.99) | 18.7374 |
| 1990's | 839 (10.43) | 18.2507 |
| 2000's | 1,484 (18.44) | 29.6817 |
| 2010's | 2,141 (26.61) | 24.3611 |
| 2020's | 1,331 (16.54) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 791 (9.12%) | 5.53% |
| Reviews | 837 (9.65%) | 6.00% |
| Case Studies | 204 (2.35%) | 4.05% |
| Observational | 47 (0.54%) | 0.25% |
| Other | 6,799 (78.35%) | 84.16% |